Dendrimers in gene delivery

Dendrimers have unique molecular architectures and properties that make them attractive materials for the development of nanomedicines. Key properties such as defined architecture and a high ratio of multivalent surface moieties to molecular volume also make these nanoscaled materials highly interesting for the development of synthetic (non-viral) vectors for therapeutic nucleic acids. Rational development of such vectors requires the link to be made between dendrimer structure and the morphology and physicochemistry of the respective nucleic acid complexes and, furthermore, to the biological performance of these systems at the cellular and systemic level. The review focuses on the current understanding of the role of dendrimers in those aspects of synthetic vector development. Dendrimer-based transfection agents have become routine tools for many molecular and cell biologists but therapeutic delivery of nucleic acids remains a challenge

Ultrasmall-in-Nano: Why Size Matters

Gold nanoparticles (AuNPs) are continuing to gain popularity in the field of nanotechnology. New methods are continuously being developed to tune the particles’ physicochemical properties, resulting in control over their biological fate and applicability to in vivo diagnostics and therapy. This review focuses on the effects of varying particle size on optical properties, opsonization, cellular internalization, renal clearance, biodistribution, tumor accumulation, and toxicity. We review the common methods of synthesizing ultrasmall AuNPs, as well as the emerging constructs termed ultrasmall-in-nano—an approach which promises to provide the desirable properties from both ends of the AuNP size range. We review the various applications and outcomes of ultrasmall-in-nano constructs in vitro and in vivo

Size-tuneable nanometric MRI contrast agents for the imaging of molecular weight dependent transport processes

Purpose: To evaluate size-tuneable nanomeric glycol-chitosan-DTPA-Gd conjugates as MRI contrast agents for the imaging of molecular weight (MW) dependent transport processes. Material & Methods: Glycol chitosans (GC) – DTPA conjugates of precisely controlled MWs were synthesised and evaluated in mice against Gd-DTPA using times series of high-resolution MRI images of trunk, head, and xenograft flank tumours. All animal studies were approved by the local ethics committee and the UK authorities. Results: GC-DTPA modification ratio was one DTPA per 3.9 – 5.13 of GC monomers. GC-DTAPGd provided overall superior contrast compared to Gd-DTPA with the duration of the enhancement depending on MW (≥ 1h for 40kD). Kidneys showed early enhancement also in the renal pelvis suggesting renal elimination. Imaging of the head with GC-DTPA-Gd allowed detailed anatomical identification of specific blood vessels in particular with the high MW agent. Sequential high-resolution isotropic imaging of established A431 xenograft flank tumours with DTPA-Gd and GC-DTPA-Gd demonstrated that the initial delivery of the contrast agents was well correlated with blood supply. Subsequent tissue transport was primarily by diffusion and was limited by molecular weight. The data also highlight the role of heterogeneity in CA distribution that was again more prominent for the high MW agent. Conclusion: GC-DTPA-Gd with identical physical chemical properties but precisely controlled MW allow isotropic high-resolution three-dimensional imaging of molecular weight dependent transport processes which could potentially lead to clinical biomarkers for molecular weight dependent drug transport and support selection of suitable tumour models for pre-clinical development

Strategies to deliver peptide drugs to the brain

Neurological diseases such as neurodegeneration, pain, psychiatric disorders, stroke, and brain cancers would greatly benefit from the use of highly potent and specific peptide pharmaceuticals. Peptides are especially desirable because of their low inherent toxicity. The presence of the blood brain barrier (BBB), their short duration of action, and their need for parenteral administration limits their clinical use. However, over the past decade there have been significant advances in delivering peptides to the central nervous system. Angiopep peptides developed by Angiochem (Montreal, Canada), transferrin antibodies developed by ArmaGen (Santa Monica, USA), and cell penetrating peptides have all shown promise in delivering therapeutic peptides across the BBB after intravenous administration. Noninvasive methods of delivering peptides to the brain include the use of chitosan amphiphile nanoparticles for oral delivery and nose to brain strategies. The uptake of the chitosan amphiphile nanoparticles by the gastrointestinal epithelium is important for oral peptide delivery. Finally protecting peptides from plasma degradation is integral to the success of most of these peptide delivery strategies

The Topical Ocular Delivery of Rapamycin to Posterior Eye Tissues and the Suppression of Retinal Inflammatory Disease

Treatment of posterior eye diseases with intravitreal injections of drugs, while effective, is invasive and associated with side effects such as retinal detachment and endophthalmitis. In this work, we have formulated a model compound, rapamycin (RAP), in nanoparticle-based eye drops and evaluated the delivery of RAP to the posterior eye tissues in a healthy rabbit. We have also studied the formulation in experimental autoimmune uveitis (EAU) mouse model with retinal inflammation. Aqueous RAP eye drops were prepared using N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan (Molecular Envelope Technology - MET) containing 0.23 ± 0.001% w/v RAP with viscosity, osmolarity, and pH within the ocular comfort range, and the formulation (MET-RAP) was stable in terms of drug content at both refrigeration and room temperature for one month. The MET-RAP eye drops delivered RAP to the choroid-retina with a Cmax of 145 ± 49 ng/g (tmax = 1 hour). The topical application of the MET-RAP eye drops to the EAU mouse model resulted in significant disease suppression compared to controls, with activity similar to dexamethasone eye drops. The MET-RAP eye drops also resulted in a reduction of RORγt and an increase in both Foxp3 expression and IL-10 secretion, indicating a mechanism involving the inhibition of Th17 cells and the up-regulation of T-reg cells. The MET-RAP formulation delivers RAP to the posterior eye segments, and the formulation is active in EAU

Some Patterns of Haemostatic Parameters Among Pregnant Women with Hypertensive Disorders in Owerri, Imo State, Nigeria

Hemostatic parameters of pregnant women with hypertensive disorders in owerri were studied using standard methods. The parameters include PT, APTT, Fibrinogen, t-PA, D-dimer. A total of 200 pregnant women between ages of 18 and 45 years of age were recruited for the study. They consisted of 50 normotensive pregnant women as the control group and 150 hypertensive as the test subjects. The test group was further divided into 3 viz; 50 chronic hypertensive, 50 gestational and 50 preeclamptic pregnant women as group as groups 1, 2 and 3 respectively.  The mean PT(secs.) values were 11.69±1.02, 11.98±0.94, 12.79±0.78 and 13.86±1.4 respectively, in control, groups 1, 2 and 3. The APTT(secs) mean values in control, groups 1, 2 and 3 were 28.59±2.33, 29.43±2.67, 30.20±2.73 and 31.52 respectively. The mean values obtained for D-dimer (ng/ml) were 191.72±41.92, 207.30±60.71, 249.52±62.08 and 268±59.51 in control, groups 1, 2 and 3 respectively. In control, fibrinogen (mg/ml) mean value obtained was 521.74±118.02, where as in the test groups, 532.97±111.40, 602.52±103.80 and 671.98±97.37 were respectively obtained in groups1, 2 and 3. The mean respective values of t-PA (ng/ml) in control, group 1, 2 and 3 were 2.43±0.55, 2.49±0.49, 2.84±0.54 and 2.90±0.57. All the haemostatic parameters: PT, APTT, Fibrinogen, D- dimer and t-PA values increased across the test groups when compared with the control groups and they were found to be statistically significant (P=0.0001). From this study, haemostatic parameters increased in the test subjects indicating inflammatory activities in hypertensive disorders of pregnancy